Goodwin Advises Pharmakon on Intellectual Property Aspects of $150 Million Loan for CorMedix
The Life Sciences IP and Private Equity teams advised Pharmakon Advisors, LP (Pharmakon) on the intellectual property aspects of its $150 million senior-secured loan facility for CorMedix Inc., a US biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The loan is intended to help finance CorMedix’s planned acquisition of Heron Therapeutics, Inc.’s commercial assets.
Pharmakon is an investment management firm specializing in providing strategic financing solutions to the life sciences industry.
The Goodwin deal team was led by Carl Morales, Kevin Grumberg, Christopher Haley, and Tyler Garaffa.
For more information on the deal, please read Pharmakon’s LinkedIn announcement.